Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Bansback

Showing results (81-90 of 203) with videos related to

Pageof 21
Sort By:
Journal of the American Academy of Dermatology|December 3, 2014
Assessing adherence with phototherapy protocolsSunil Kalia, Bez Toosi, Nick Bansback, et al.
Cost Effectiveness and Resource Allocation : C/E|September 15, 2017
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimatesStephanie Harvard, Daphne Guh, Nick Bansback, et al.
Patient Preference and Adherence|November 6, 2020
Patient-Reported Outcome Measures (PROMs) to Support Adherence to Falls Prevention Clinic Recommendations: A Qualitative StudyDaria Tai, Eric Li, Teresa Liu-Ambrose, et al.
ACR Open Rheumatology|October 26, 2020
Comorbidities Before and After the Diagnosis of Rheumatoid Arthritis: A Matched Longitudinal StudyMark R Tatangelo, George Tomlinson, Edward Keystone, et al.
Clinical Rheumatology|April 6, 2020
Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-makingMark Harrison, Nick Bansback, Magda Aguiar, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 20, 2022
Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage dataAlison R McClean, Michael R Law, Mark Harrison, et al.
RMD Open|April 22, 2016
Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohortStephanie Harvard, Daphne Guh, Nick Bansback, et al.
Arthritis and Rheumatism|April 3, 2008
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysisAllan J Wailoo, Nick Bansback, Alan Brennan, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 26, 2015
Exclusion Criteria in National Health State Valuation Studies: A Systematic ReviewLidia Engel, Nick Bansback, Stirling Bryan, et al.
BMC Medical Research Methodology|March 31, 2021
Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ARTSteve Kanters, Mohammad Ehsanul Karim, Kristian Thorlund, et al.
Pageof 21

Showing results (81-90 of 203) with videos related to

Sort By:
Pageof 21
Journal of the American Academy of Dermatology|December 3, 2014
Assessing adherence with phototherapy protocolsSunil Kalia, Bez Toosi, Nick Bansback, et al.
Cost Effectiveness and Resource Allocation : C/E|September 15, 2017
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimatesStephanie Harvard, Daphne Guh, Nick Bansback, et al.
Patient Preference and Adherence|November 6, 2020
Patient-Reported Outcome Measures (PROMs) to Support Adherence to Falls Prevention Clinic Recommendations: A Qualitative StudyDaria Tai, Eric Li, Teresa Liu-Ambrose, et al.
ACR Open Rheumatology|October 26, 2020
Comorbidities Before and After the Diagnosis of Rheumatoid Arthritis: A Matched Longitudinal StudyMark R Tatangelo, George Tomlinson, Edward Keystone, et al.
Clinical Rheumatology|April 6, 2020
Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-makingMark Harrison, Nick Bansback, Magda Aguiar, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 20, 2022
Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage dataAlison R McClean, Michael R Law, Mark Harrison, et al.
RMD Open|April 22, 2016
Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohortStephanie Harvard, Daphne Guh, Nick Bansback, et al.
Arthritis and Rheumatism|April 3, 2008
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysisAllan J Wailoo, Nick Bansback, Alan Brennan, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 26, 2015
Exclusion Criteria in National Health State Valuation Studies: A Systematic ReviewLidia Engel, Nick Bansback, Stirling Bryan, et al.
BMC Medical Research Methodology|March 31, 2021
Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ARTSteve Kanters, Mohammad Ehsanul Karim, Kristian Thorlund, et al.
Pageof 21